Inhibition of Histone Demethylase JMJD1A Improves Anti-Angiogenic Therapy and Reduces Tumor-Associated Macrophages
Authors:
- Tsuyoshi OsawaTOTsuyoshi Osawa
- Rika TsuchidaRTRika Tsuchida
- Masashi MuramatsuMMMasashi Muramatsu
- Teppei ShimamuraTSTeppei Shimamura
- Feng WangFWFeng Wang
- Jun-Ichi SuehiroJSJun-Ichi Suehiro
- Yasuharu KankiYKYasuharu Kanki
- Youichiro WadaYWYouichiro Wada
- Yasuhito YuasaYYYasuhito Yuasa
- Hiroyuki AburataniHAHiroyuki Aburatani
- Satoru MiyanoSMSatoru Miyano
- Takashi MinamiTMTakashi Minami
- 12 May 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (10) , 3019-3028
Abstract
Antiangiogenic strategies can be effective for cancer therapy, but like all therapies resistance poses a major clinical challenge. Hypoxia and nutrient starvation select for aggressive qualities that may render tumors resistant to antiangiogenic attack. Here, we show that hypoxia and nutrient starvation cooperate to drive tumor aggressiveness through epigenetic regulation of the histone demethylase JMJD1A (JHDM2A; KDM3A). In cancer cells rendered resistant to long-term hypoxia and nutrient starvation, we documented a stimulation of AKT phosphorylation, cell morphologic changes, cell migration, invasion, and anchorage-independent growth in culture. These qualities associated in vivo with increased angiogenesis and infiltration of macrophages into tumor tissues. Through expression microarray analysis, we identified a cluster of functional drivers such as VEGFA, FGF18, and JMJD1A, the latter which was upregulated in vitro under conditions of hypoxia and nutrient starvation and in vivo before activation of the angiogenic switch or the prerefractory phase of antiangiogenic therapy. JMJD1A inhibition suppressed tumor growth by downregulating angiogenesis and macrophage infiltration, by suppressing expression of FGF2, HGF, and ANG2. Notably, JMJD1A inhibition enhanced the antitumor effects of the anti-VEGF compound bevacizumab and the VEGFR/KDR inhibitor sunitinib. Our results form the foundation of a strategy to attack hypoxia- and nutrient starvation–resistant cancer cells as an approach to leverage antiangiogenic treatments and limit resistance to them. Cancer Res; 73(10); 3019–28. ©2013 AACR.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?Cell, 2012
- Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesisProceedings of the National Academy of Sciences, 2011
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Human glioblastoma cells exposed to long-term hypoxia and nutrient starvation stimulated induction of secondary T-cell leukemia in miceBlood Cancer Journal, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse modelsProceedings of the National Academy of Sciences, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993